Group 1 - The company, HaiXi Pharmaceutical (02637.HK), plans to globally offer 11.5 million shares, with 1.15 million shares available in Hong Kong and 10.35 million shares for international sale [1] - The subscription period is from October 9 to October 14, with a maximum offer price of HKD 86.40 per share, and the entry fee is approximately HKD 4,363.57 for a trading unit of 50 shares [1] - The total expected fundraising amount is HKD 899 million, with a net amount of HKD 848 million, which will be used for ongoing R&D investments, enhancing R&D capabilities, seeking collaboration opportunities, and improving commercialization and production systems [1] Group 2 - The company has introduced cornerstone investors, including Harvest Oriental SP, who will subscribe to approximately 198,170 shares at the offer price [1] - The company is expected to be listed on the main board on October 17, 2025, with Huatai Financial Holdings (Hong Kong) and China Merchants Jinling International as joint sponsors [1] - The company is a commercial-stage pharmaceutical firm with integrated R&D, production, and sales capabilities, possessing a diverse product portfolio and pipeline in China's largest and fastest-growing therapeutic areas [1] Group 3 - The company's net profits for the fiscal years ending December 31 are projected to be CNY 68.981 million for 2022, CNY 117 million for 2023, and CNY 136 million for 2024 [2]
海西新药(02637.HK)拟全球发售1150.00万股 10月9日起招股